drugset / Trial / NCT02256774

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

NCT02256774

Phase 1 Completed 51 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to determine the effect of BILR 355/r on Combivir® pharmacokinetics and the effect of Combivir® on BILR 355 BS pharmacokinetics.

Timeline

Start
2004-10
Primary completion
2005-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown
Subject Lamivudine Other / unclassified
Subject ZDV Unknown
Background Ritonavir Other / unclassified

Indications

No indication recorded.